Pharmacological reactivation of p53 as a strategy to treat cancer |
| |
| Authors: | J. Zawacka‐Pankau G. Selivanova |
| |
| Affiliation: | Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden |
| |
| Abstract: | It has been confirmed through studies using the technique of unbiased sequencing that the TP53 tumour suppressor is the most frequently inactivated gene in cancer. This finding, together with results from earlier studies, provides compelling evidence for the idea that p53 ablation is required for the development and maintenance of tumours. Genetic reconstitution of the function of p53 leads to the suppression of established tumours as shown in mouse models. This strongly supports the notion that p53 reactivation by small molecules could provide an efficient strategy to treat cancer. In this review, we summarize recent advances in the development of small molecules that restore the function of mutant p53 by different mechanisms, including stabilization of its folding by Apr‐246, which is currently being tested in a Phase II clinical trial. We discuss several classes of compounds that reactivate wild‐type p53, such as Mdm2 inhibitors, which are currently undergoing clinical testing, MdmX inhibitors and molecules targeting factors upstream of Mdm2/X or p53 itself. Finally, we consider the clinical applications of compounds targeting p53 and the p53 pathway. |
| |
| Keywords: | anticancer therapy p53 targeted drugs transcription factor tumour suppression |
|
|
